| Misconception | TR 82 Clarification | |---------------|----------------------| | "LER means my LAL test is broken." | No—LER is a product interaction phenomenon, not a test failure. | | "All LER is harmless." | False. Some LER masks pyrogenic endotoxins. Requires case-by-case risk assessment. | | "Just use rFC instead of LAL to fix LER." | Both LAL and rFC suffer equally from LER because the mechanism is biochemical masking, not reagent specificity. | | "The FDA rejects products with LER." | Incorrect. The FDA accepts products with LER if properly documented and justified using TR 82 principles. |
Ensure that third-party logistics (3PL) providers operate under GDP (Good Distribution Practice) conditions that align with TR 82 standards. pda technical report 82 pdf
utilizing mRNA and viral vector technologies. Requires case-by-case risk assessment